Release advantages of a liposomal dendrimer-doxorubicin complex, over conventional liposomal formulation of doxorubicin

Nanomaterials and Nanosystems for Biomedical Applications

Volumn , Issue , 2007, Pages 135-144

  Papagiannaros, Aristarchos ^a   Demetzos, Costas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

dendrimer; doxorubicin; drug release; Liposome; PAMAM G4

Indexed keywords

EID: 52949145437     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-6289-6_9     Document Type: Chapter

References (28)

1. Andresen, T., Jensen, S., Jorgensen, K. (2005) Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. Progress in Lipid Research, 44, 68-97.
2. Aulenta, F., Hayes, W., Rannard, S. (2003) Dendrimers a new class of nanoscopic containers and delivery devices. European Polymer Journal, 39, 1741-1771.
3. Charrois, G., Allen, T. (2004) Drug Release rate influences the pharmacokinetics, biodistribution, therapeutic activity and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim. Biophys. Acta, 1663, 167-177.
4. Cloninger, M. (2002) Biological application of dendrimers. Current Opinion in Chemical Biology, 6, 742-748.
5. Dhoot, N., Wheatley, M. (2003) Microencapsulated liposomes in controlled drug delivery strategies to modulate drug release and eliminate the burst effect. J. Pharm. Sciences, 92(3), 679-689.
6. Eichman, J., Bielinska, A., Kukowska-Latallo, J., Donovan, B., Baker, J. (2001) in Frechet, J. and Tomalia, D. (eds.) Dendrimers and other Demdritic Polymers. J. Wiley & Sons, Chisester, 441-462.
7. Gabizon, A. (2002) Liposomal drug carriers in cancer chemotherapy: current status and future prospects. The Journal of Drug Targetting, 10(7), 535-538.
8. Goniotaki, M., Hatziantoniou, S., Dimas, K., Wagner, M., Demetzos, C. (2004) Encapsulation of naturally occurring flavonoids into liposome: Physicochemical characterization and biological activity against human cancer cell lines. J. Pharm. Pharmacol., 56, 1217-1224.
9. Horovic, A., Barenholtz, A., Gabizon, A. (1992) In vitro cytotoxicity of liposome encapsulaterd doxorubicin: dependence on liposomes composition and drug release. Biochima et Biophysica Acta, 1109, 203-209.
10. Khuloud Al-J., Sakthivel, T., Florence, A. T. (2003) Dendrisomes: cationic lipidic dendron vesicular assemblies. International Journal of Pharmaceutics, 254, 33-36.
11. Klopade, A., Caruso, F., Tripathi, P., Nagaish, S., Jain, N. (2002) Effect of dendrimer on entrapment and release of bioactive from liposome. Int. J. Pharm., 232, 157-162.
12. Kolhe, P., Khandarea, J., Omathanu, O., Kannanb, S., Lieh-Laib, M., Rangaramanujam, M. (2007) Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with ahigh drug payload Biomaterials, (in press).
13. Mayer, L., Bally, M. (1986) Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochimica et Biophysica Acta, 123-126.
14. Ohvo-Rekila, H., Ramsted, B., Leppimaki, P., Slotte, P. (2002) Cholesterol interaction with phospholipids in membranes. Progress in Lipid Research, 41, 66-97.
15. Oussoren, C., Eling, W., Crommelin, D., Storm, G., Zuidema, J. (1998) The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue against local toxicity of two antitumor drugs. Biochimica et Biophysica Acta, 1369, 159-172.
16. Pan, X., Lee, R., Rantman, M. (2004) Penetration into solid tumor tissue of fluorescent latex microspheres: a mimic of liposome particles. Anticancer Research, 24, 3503-3508.
17. Papagiannaros, A., Dimas, K., Papaioannou, G., Demetzos, C. (2005) Doxorubicin-PAMAM dendrimer complex attached to liposomes and cytotoxic studies against human cancer cell lines. Int. J. Pharm, 302, 29-38.
18. Papagiannaros, A., Hatziantoniou, S., Dimas, K., Papaioannou, G., Demetzos, C. (2006) A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines. Biomedicine & Pharmacotherapy, 60(1), 36-42.
19. Purohit, G., Sakthivel, T., Florence, A. T. (2001) Interaction of cationic partial dendrimers with charged and neutral liposomes. Int. J. Pharm, 214, 71-76.
20. Quintan, A., Raczka, L., Piehler, L., Lee, I., Myc, A., Majoros, I., Patri, A., Thomas, T., Mule, J., Baker, J. (2002) Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells though the folate receptor. Pharmaceutical Research, 19(9), 1310-1316.
21. Sadzuka, Y., Hirama, R., Sonobe, T. (2002) Effects of intraperitoneal administration of liposomes and methods of preparing liposomes for local therapy. Toxicology Letters, 126, 83-90.
22. Sideratou, Z., Foundi, J., Tsiourvas, D., Nezis, I., Papadimas, G., Paleos, C. (2002) A novel dendrimeric glue for adhesion of phosphatidyl choline based liposomes. Langmuir, 18, 5036-5039.
23. Singh, B., Florence, A. T. (2005) Hydrophobic dendrimer-derived nanoparticles Int. J. Pharm., 298, 348-353.
24. Stenekes, R., Loebis, A., Fernades, C., Crommelin, D., Hennik, W. (2002) Controlled release of liposomes from biodegradable dextran microspheres. Pharmaceutical Research, 17(6), 690-695.
25. Straubinger, R., Arnold, R., Zhou, R., Mazurchuk, R., Slack, J. (2004) Antivascular and antitumor activities of liposome associated drugs. Anticancer Research 24, 397-404.
26. Syrigos, K., Michalaki, B., Alevyzaki, F., Macheras, A., Mandrekas, D., Kindilis, K., Karatzas, G. G. (2002) A Phase II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer. Anticancer Research, 22, 3583-3588.
27. Szoka, F., Papahadjopoulos, D. (1978) Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc. Natl. Acad. Sci. USA, 75(9), 4194-4198.
28. Toma, S., Tucci, A., Villani, G., Carteni, G., Spadini, N., Palumbo, R. (2002) Liposomal doxorubicin (caelyx) in advanced pretreated soft sarcomas: a phase II study of the Italia sarcoma group (ISG). Anicancer Research, 20, 485-492.